Coronavirus Update: India Approves Remdesivir, Ex-Biogen Employee Charged
Plus: China Secures Vaccines Manufacturing
Executive Summary
A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.
You may also be interested in...
Biogen’s Boston Meeting Was COVID Superspreader Event
The February meeting confirmed as source for around 20,000 cases across Boston, the US and internationally.
Remdesivir Rivals Hit Indian Market
Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.
Hetero, Cipla's Remdesivirs Hit India Market, 'Surplus' Envisaged By August
Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.